VANCOUVER, British Columbia--(BUSINESS WIRE)--Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, today announce the appointment of Najla Guthrie to the Benzinga Psychedelic Advisory Council.
The Benzinga Psychedelics Advisory Council is a collective of the leading minds and voices in the psychedelics space, composed of key thought leaders sharing insights into industry developments, sector trends and breaking news.
"We are delighted to add Najla Guthrie to this highly respected council, representing the leading voices in the emerging sector of psychedelic medicine," said Patrick Lane, Executive Vice President of Partnerships at Benzinga.
"Benzinga continues to be a leading platform for coverage of the psychedelic space and continues to be a hub where investors come to identify their next investment opportunities. I am honoured to be amongst esteemed colleagues and thought leaders in the space,” added Najla Guthrie, CEO of Wellbeing Digital Sciences.
Members Of the Benzinga Psychedelics Advisory Council
The Benzinga Psychedelics Advisory Council includes:
Najla Guthrie, CEO of Wellbeing Digital Sciences (NEO.MEDI)
Rob Barrow, CEO of Mind Medicine Inc. (NASDAQ:MNMD)
Florian Brand, Co-Founder and CEO of Atai Life Sciences (NASDAQ:ATAI)
Berner, Rapper and CEO of Caps by Cookies
Andrew Chadeayne, Founder and Chief Executive Officer at CaaMTech
Yaron Conforti, Co-Founder and CEO of Novamind (CSE: NM) (OTCQB:NVMDF)
Anne Donohoe, Managing Director, KCSA Strategic Communications
Doug Drysdale, Chief Executive Officer at Cybin Inc. (NYSE:CYBN)
Ronan Levy, Co-Founder and Executive Chairman of Field Trip Health (NASDAQ:FTRP)
Payton Nyquvest, Founder and CEO at Numinus (TSX: NUMI)
Graham Pechenik, Patent Attorney and Founder of Calyx Law
Natan Ponieman, Head of Psychedelics Content at Benzinga
Kelsey Ramsden, CEO and President of Mind Cure Health (CSE:MCUR) (OTCQX:MCURF)
Aaron Raub, Partner and Portfolio Manager, Ambria Capital
Tim Regan, SVP Capital Markets, KCSA Strategic Communications
Tim Schlidt, Co-Founder and Partner, Palo Santo Fund
Joseph Tucker, CEO of Enveric Biosciences (NASDAQ:ENVB)
What Is The Benzinga Psychedelics Advisory Council?
The Benzinga Psychedelics Advisory Council honors some of the greatest leaders in the burgeoning psychedelics industry and gives Benzinga readers and Benzinga Psychedelics Capital Conference attendees even more access to credible industry insights.
Members of the Benzinga Psychedelics Advisory Council will share their expertise through a series of articles, opinion pieces, live conversations at the Benzinga Psychedelics Capital Conference, and quotes on relevant news.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content. The Benzinga Psychedelics Capital Conference is the premier gathering of psychedelics industry leaders and forward-thinking investors. The event brings unique networking opportunities with top investors and executives in the space. Its first edition is coming to the Fontainebleau Miami Beach on April 19, 2022, in Miami, Florida.
ABOUT WELLBEING DIGITAL SCIENCES
Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. For additional information, please visit wellbeingdigital.co.
On behalf of:
Chief Executive Officer
WELLBEING DIGITAL SCIENCES
VP of Marketing & Investment Relations
Notice Regarding Forward-Looking Information:
This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.
The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.